Nanjing Univ. of Chinese Medicine FLT3 compound F15

Nanjing Univ. of Chinese Medicine FLT3 compound F15: sourced facts only. name: "Among these derivatives, compound F15 displayed potent inhibition activities against FLT3 (IC50 = 123 nM) and FLT3-internal tandem duplication (ITD) by 80% and 26.06%, respectively, at the concentration of 1 μM." [PMID:36644989]; target: "Among these derivatives, compound F15 displayed potent inhibition activities against FLT3 (IC50 = 123 nM) and FLT3-internal tandem duplication (ITD) by 80% and 26.06%, respectively, at the concentration of 1 μM." [PMID:36644989]; developer: "National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China." [PMID:36644989]; modality: "Small molecule covalent drugs have proved to be desirable therapies especially on drug resistance related to point mutations." [PMID:36644989]; stage: "Besides, F15 exhibited potent activity against FLT3-dependent human acute myeloid leukemia (AML) cell lines MOLM-13 (IC50 = 253 nM) and MV4-11 (IC50 = 91 nM), as well as BaF3 cells with variety of secondary mutations." [PMID:36644989]